💲 Bitcoin could become 'currency of choice' for global trade
Today’s Picks
Bitcoin is at a tipping point and could become 'currency of choice' for global trade, Citi says. Citi thinks bitcoin is at a “tipping point” and could one day “become the currency of choice for international trade” as firms like Tesla and PayPal warm to it and central banks explore issuing their own digital currencies. (Ryan Browne via CNBC)
Space startup Gitai raises $17.1M to help build the robotic workforce of commercial space. Japanese space startup Gitai has raised a $17.1 million funding round, a Series B financing for the robotics startup. (Darrell Etherington via TechCrunch)
Former French President Sarkozy Convicted in Corruption Trial. Former French President Nicolas Sarkozy was found guilty Monday of trying to bribe a magistrate, becoming the first president in the history of France’s post-World War II republic to face prison time. (Noemie Bisserbe via Wall Street Journal)
New AI 'Deep Nostalgia' brings old photos, including very old ones, to life. An AI-powered service called Deep Nostalgia that animates still photos has become the main character on Twitter this fine Sunday, as people try to create the creepiest fake “video” possible, apparently. (Kim Lyons via The Verge)
Irrational Nuclear Fear Puts Sweden In Danger Of Succumbing To Stupidity. No one has ever died because of Swedish nuclear power. Until recently, nuclear power provided about 40% of that country’s electricity, similar to hydro. Fossil fuels only generated about 1% of Sweden’s electricity. (James Conca via Forbes)
Goldman's Consumer Chief Ismail Makes Shock Exit for Walmart. Walmart Inc. has lured a pair of senior Goldman Sachs bankers to help lead a new fintech startup as the retail giant muscles into the banking business. (Sridhar Natarajan via Bloomberg)
Vaccine Hesitancy Isn't Just One Thing. Why wouldn’t someone want a COVID-19 vaccine? Staring at the raw numbers, it doesn’t seem like a hard choice. Thousands of people are dying of COVID-19 every day. Meanwhile, out of the 75,000 people who received a shot in the vaccine trials from Pfizer-BioNTech, Moderna, AstraZeneca, Johnson & Johnson, and Novavax, zero died and none were hospitalized after four weeks. (Derek Thompson via The Atlantic)
👋 Hello. We're Newslit
Want to stay on top of your Industry News? Newslit next-generation news monitoring tool makes it easy to monitor the web for breaking news headlines and interesting new content to help you hone in on your industry, competitors and brands for accurate market research.
Also, follow us on Twitter and check in through the day to find out what’s interesting in Media & Journalism